April 23, 2006
Next Wave of Pharmaceutical Litigation
While most of the public attention recently has been focused on the Vioxx trials, a New York Times article on Saturday reports that there are several other drugs still on the market that will be the subject of more high-stakes litigation because of what plaintiffs' lawyers say involve either hidden and severe side effectst or improper marketing of the drugs. The drugs include AstraZeneca's Seroquel, which is an antipsychotic medicine, Johnson & Johnson's Ortho-Evra, a birth control patch, Wheth's Prempro, a hormone therapy for women; and Merck's Fosamax, an osteoperosis medicine. The combined annual sales of the drugs total almost $7 billion. They are used by millions of patients, creating a significant pool for litigation. By Alex Berenson.
April 23, 2006 | Permalink
TrackBack URL for this entry:
Listed below are links to weblogs that reference Next Wave of Pharmaceutical Litigation: